How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...
Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...
My computer coding education ended in a high school classroom in the early 2000s, when I created a game in which two camels spit at one another. The experience of typing every line of code was ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback